Correlative Studies with Specimens from Multi-Site Trials (R21)
Post Date
April 4th 2008
Application Due Date
May 7th 2011
Funding Opportunity Number
PA-08-133
CFDA Number(s)
93.393
93.394
93.395
Funding Instrument Type(s)
Grant
Funding Activity Categories
Eligibility Categories
State Governments
Public and State Controlled Institutions of Higher Education
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government Non-domestic (non-U.S.) Entities (Foreign Organizations) Regional Organizations U.S. Territory or Possession
Funding
-
Award Range:
$None - $200000
Grant Description
-Purpose. This Funding Opportunity Announcement (FOA) is intended to support translational correlative studies that utilize annotated tumor and/or other biospecimens collected during large-scale multi-institutional clinical and/or prevention trials, respectively. The Cancer Therapy Evaluation Program (CTEP), the Cancer Diagnosis Program (CDP), and the Cancer Biomarkers Research Group (CBRG) of the NCI are cooperatively sponsoring this FOA with the overarching goal to facilitate predictions of responses to current interventions, and inspire future development of improved therapeutic and preventive strategies. Projects proposed in response to this FOA should address the correlations between intervention outcomes and cancer patients disease characteristics determined at various cellular/molecular levels. For example, disease progression patterns may be correlated with tumor genotypic and/or phenotypic profiles (at the levels of the genome, epigenome, gene expression and/or protein and non-protein molecular markers.ÊThis FOA will only support studies that use tumor specimens linked to specific interventions/trials. To be able to achieve these translational goals, the proposed projects are expected to rely on interactions between basic researchers and clinical investigators, in order to improve future drug development and interventions. -Mechanism of Support. This FOA utilizes the NIH Exploratory/Developmental Grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-08-134, that solicits applications under the NIH Research Project Grant (R01) mechanism.
Contact Information
-
Agency
Department of Health and Human Services
-
Office:
National Institutes of Health
-
Agency Contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV -
Agency Mailing Address:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Agency Email Address:
- More Information:
Get A Free Grant Assistance Kit
To start your application for a free grant package go to: